Recent advances in radiation therapy of pancreatic cancer [version 1; peer review: 2 approved]

Pancreatic cancer has a dismal prognosis with an overall survival outcome of just 5% at five years. However, paralleling our improved understanding of the biology of pancreatic cancer, treatment paradigms have also continued to evolve with newer advances in surgical techniques, chemotherapeutic agen...

Full description

Saved in:
Bibliographic Details
Published inF1000 research Vol. 7; p. 1931
Main Authors Venkatesulu, Bhanu Prasad, Hsieh, Cheng-En, Sanders, Keith L, Krishnan, Sunil
Format Journal Article
LanguageEnglish
Published England Faculty of 1000 Ltd 2018
F1000 Research Limited
Subjects
Cancer therapies
Chemoradiotherapy
Chemotherapy
Clinical trials
Immunotherapy
Lymphopenia
Medical prognosis
Metastasis
Oncology
Pancreatic cancer
Radiation therapy
Review
Spleen
Surgery
Veins & arteries
United States > US
radiotherapy
Dose escalation
spleen sparing
neoadjuvant therapy
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Pancreatic cancer has a dismal prognosis with an overall survival outcome of just 5% at five years. However, paralleling our improved understanding of the biology of pancreatic cancer, treatment paradigms have also continued to evolve with newer advances in surgical techniques, chemotherapeutic agents, radiation therapy (RT) techniques, and immunotherapy paradigms. RT dose, modality, fraction size, and sequencing are being evaluated actively, and the interplay between RT and immune effects has opened up newer avenues of research. In this review, we will emphasize recent advances in RT for pancreatic cancer, focusing on preoperative chemoradiation, RT dose escalation, sparing of the spleen to reduce lymphopenia, and combination of RT with immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
No competing interests were disclosed.
ISSN:2046-1402
2046-1402
DOI:10.12688/f1000research.16272.1